NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas

BACKGROUND: The determination of NRAS and BRAF mutation status is a major requirement in the treatment of patients with metastatic melanoma. Mutation specific antibodies against NRAS(Q61R) and BRAF(V600E) proteins could offer additional data on tumor heterogeneity. The specificity and sensitivity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Uguen, Arnaud, Talagas, Matthieu, Costa, Sebastian, Samaison, Laura, Paule, Laure, Alavi, Zarrin, De Braekeleer, Marc, Le Marechal, Cédric, Marcorelles, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513673/
https://www.ncbi.nlm.nih.gov/pubmed/26204954
http://dx.doi.org/10.1186/s13000-015-0359-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513673/
https://www.ncbi.nlm.nih.gov/pubmed/26204954
http://dx.doi.org/10.1186/s13000-015-0359-0

Ejemplares similares